Lilly suspends Phase III melanoma trial with new anticancer after deaths
This article was originally published in Scrip
Executive Summary
Lilly has suspended the first Phase III trial of its experimental drug tasisulam, testing it as a second-line treatment in patients with unresectable or metastatic melanoma, after 12 deaths which were potentially treatment-related were observed.